Shop by goal
Popular compounds
Research resources
Recently viewed
Tirzepatide: Metabolic / Fat Loss research guide
In short: Tirzepatide, dual GIP/GLP-1 receptor agonist with imbalanced agonism favouring GIP, with body-composition reductions reported in published research. It is studied in preclinical (cell and animal) research and is supplied strictly for laboratory use — not for human or clinical use.
Not medical advice. Tirzepatide is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.
Tirzepatide at a glance
What Tirzepatide is
Tirzepatide combines GLP-1 and GIP activity in one molecule; papers highlight dual incretin mechanisms and metabolic endpoints in controlled studies.
One-paragraph overview from our research datasheet — still scientific, but faster to read than the full mechanism list below.
Tirzepatide, dual GIP/GLP-1 receptor agonist with imbalanced agonism favouring GIP, with body-composition reductions reported in published research.
Quick takeaways
Research contexts
Peer-reviewed literature typically discusses Tirzepatide in specific experimental settings. The points below reflect how the scientific community frames this compound—not as health claims, but as the research questions being asked.
Research vs. personal use: Literature describes experiments in controlled lab and animal models. This is distinct from any real-world use; our products are for laboratory research only.
Typical study contexts
Why Metabolic / Fat Loss research matters
Metabolic peptides in this category are investigated for appetite signalling, incretin pathways, and energy balance in research models. Literature emphasises mechanisms rather than lifestyle advice.
Mechanisms (technical review)
Our datasheet lists mechanistic themes observed in preclinical work. These are research endpoints, not health claims. They help scientists understand and compare pathways.
Lab handling & preparation
Storage requirements: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. · Learn best practices in our detailed storage guide.
Research dosing context: Literature typically discusses 2.5–15 mg subcutaneously (dose escalation) · Once weekly subcutaneous injection · t½ ≈ 5 days (116.7 h mean); Tmax = 8–72 h; Vd ≈ 10.3 L; 99% albumin bound; bioavailability ~80%; dose escalation: 2.5 mg × 4 wk → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg. Metabolized via proteolytic cleavage, C20 diacid β-oxidation, and amide hydrolysis; ~66% renal / ~33% fecal elimination as metabolites.
Preparation steps: Follow our detailed reconstitution guide, use the calculator tool for volume confirmation, and always verify purity with the COA reading guide.
Common Questions People Are Asking
What is tirzepatide?
Tirzepatide is a dual GIP and GLP-1 receptor agonist (a "twincretin") — the peptide best known as the active ingredient in Eli Lilly's Mounjaro and Zepbound. Tirzepatide is the research-grade form of this tirzepatide peptide, supplied as a lyophilised powder strictly for in-vitro and preclinical laboratory research. It is NOT Mounjaro or Zepbound, is not an approved medicine, and is not for human use.
How does tirzepatide work?
In the published literature tirzepatide activates both the GIP and GLP-1 receptors, combining their satiety, insulin-secretion and adipose-tissue effects — which is why it is described as a "dual incretin" agonist. These are mechanisms reported for the molecule in research, not human-use guidance; Tirzepatide is supplied for laboratory research only.
Is tirzepatide a GLP-1?
Not exactly — tirzepatide is a DUAL agonist: it activates both the GIP receptor and the GLP-1 receptor, whereas semaglutide activates GLP-1 alone. That second (GIP) arm is the key structural difference. Tirzepatide is the research-grade tirzepatide peptide, supplied for research use only.
Is Tirzepatide the same as Mounjaro or Zepbound?
It is the same active peptide (tirzepatide) but NOT the same product. Mounjaro and Zepbound are FDA-approved, prescription, sterile finished pharmaceuticals made under cGMP. Tirzepatide is an unapproved, research-grade lyophilised powder sold for laboratory research only — not for human consumption and not a substitute for any prescribed medication.
How is Tirzepatide different from Semaglutide?
Semaglutide activates only the GLP-1 receptor. Tirzepatide activates both the GLP-1 and GIP receptors. The added GIP receptor activity drives additional satiety and adipose-tissue effects, producing larger weight loss and HbA1c reductions in published research — for example, the head-to-head SURMOUNT-5 trial (NEJM 2025) reported 20.2% versus 13.7% body-weight reduction at 72 weeks.
Tirzepatide vs retatrutide — what is the difference?
Tirzepatide is a dual GIP/GLP-1 agonist, while retatrutide is a triple agonist that adds a third arm — the glucagon receptor — on top of GIP and GLP-1. In its respective Phase 2 obesity programme retatrutide reported larger mean body-weight reductions than tirzepatide did in SURMOUNT-1, but retatrutide remains earlier in clinical development. Both are described in the literature as descriptive context; each is supplied here only as unapproved, research-grade material for laboratory use, not for human use.
Why is Tirzepatide described as imbalanced?
It is a full agonist at GIPR (comparable potency to native GIP) but biased at GLP-1R, favouring cAMP signalling over β-arrestin recruitment. The asymmetry preserves the GIP arm while reducing the receptor desensitisation that can blunt long-term efficacy at GLP-1R.
How is Tirzepatide stored?
Keep the lyophilised powder at −20 °C in the freezer. After reconstitution with bacteriostatic water, refrigerate at 1-6 °C and protect from light. Avoid repeated freeze-thaw cycles, which can damage the fatty acid tail and reduce potency.
What happens when you stop taking GLP-1s?
Published trials of the reference drug (the SURMOUNT-4 withdrawal study of tirzepatide) report that stopping a GIP/GLP-1 receptor agonist leads to a return of appetite and substantial regain of lost weight over the following months, as the dual receptor stimulation that suppressed appetite and slowed gastric emptying ends. Those findings describe the approved medicine in human studies — Tirzepatide is an unapproved research-grade peptide for laboratory research only and is not for human use.
Is this page medical advice? Can I use Tirzepatide for my health?
No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.
Where do I find Tirzepatide specs, purity certificates and pricing?
Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.
Related peptide guides
Other compounds researchers often read about alongside Tirzepatide.
Scientific sources & further reading
Primary literature and registries for Tirzepatide, plus mainstream coverage of the peptide category. Research use only - not medical advice.
Databases & literature:
Peptides in the news:
Ready to order? View full product specs
Access concentration, batch info, variants, and current pricing on our shop.
Also known as: GIP/GLP-1 Dual Agonist, Dual Incretin Agonist, Twincretin
Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.
Shop
Learn
Company
Support
Ways to Pay
Shop by Compound
Shop by Goal
Ships worldwide
Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.
All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.
Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.
© 2026 New-U Research Compounds · new-u.io · @new.u.io